得益於新冠肺炎疫苗強勁需求 Moderna(MRNA.US)第二季度營收增長9%
格隆匯8月3日丨Moderna(MRNA.US)公佈,截至6月30日,二季度淨利潤為22億美元(合每股5.24美元),同比降26.36%,但高於華爾街分析師此前預計的4.70美元,原因是與過期疫苗劑量相關的費用以及購買承諾的改變;收入為47.5億美元,同比增長98%,超過了華爾街分析師的預期,其中產品銷售額(COVID-19疫苗銷售額)同比增長8%至45.3億美元(市場估計為38.2億美元),主要是受客户組合導致的平均銷售價格上升推動。另外,董事會批准了一項額外的30億美元的股票回購計劃。Moderna首席執行長Stephane Bancel説,公司有預購協議,今年的銷售額約為210億美元。受Moderna更新的新冠肺炎疫苗的批准時機以及相關製造能力提升的推動,預計今年最後一個季度的銷售將比當前季度加快。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.